Treatment Type: Targeted Therapy

Mobocertinib

Targeted TherapyApproved for: NSCLCBiomarker: EGFR Exon20 Insertion Mobocertinib (EXKIVITY) is the first oral therapy specifically designed for patients with EGFR Exon20 insertion+ NSCLC Related Research News FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1+ NSCLCClinical Research Demonstrates Positive...
Read More
|
January 5, 2022
|
Treatment

Sotorasib

Targeted TherapyApproved for: NSCLCBiomarker: KRAS G12C Sotorasib is the first treatment for adult patients with non–small cell lung cancer whose tumors harbor KRAS G12C mutations and who have received at least 1 prior systemic therapy. Related Research News FDA...
Read More
|
January 5, 2022
|
Treatment

Gefitinib (Iressa)

Targeted TherapyApproved for: NSCLCBiomarker: EGFR Gefitinib (Iressa) approved Targeted Therapy for non-small cell lung cancer (NSCLC) that has metastasized (spread to other parts of the body). It is used as first-line treatment in patients whose tumors have certain EGFR...
Read More
|
June 1, 2021
|
Treatment

Erlotinib (Tarceva)

Targeted TherapyApproved for: NSCLCBiomarker: EGFR Erlotinib (Tarceva) approved Targeted Therapy for Non-small cell lung cancer (NSCLC) that is metastatic and has certain EGFR gene mutations. It may be used: As first-line therapy. In patients on maintenance therapy or whose...
Read More
|
June 1, 2021
|
Treatment

Crizotinib (Xalkori)

Targeted TherapyApproved for: NSCLCBiomarker: ALK, ROS1 Crizotinib (Xalkori) approved Targeted Therapy for Non-small cell lung cancer (NSCLC) that is ALK positive or ROS1 positive and has metastasized (spread to other parts of the body). Related Research News FDA Approves...
Read More
|
May 31, 2021
|
Treatment

Ceritinib (Zykadia)

Targeted TherapyApproved for: NSCLCBiomarker: ALK Ceritinib (Zykadia) is a FDA-approved Targeted Therapy for Non-small cell lung cancer (NSCLC) that is ALK positive and has metastasized (spread to other parts of the body). It is used in adults. Related Research...
Read More
|
May 31, 2021
|
Treatment

Alectinib (Alecensa)

Targeted TherapyApproved for: NSCLCBiomarker: ALK Alectinib (Alecensa) is a FDA-approved Targeted Therapy for Non-small cell lung cancer (NSCLC) that is ALK positive and has metastasized (spread to other parts of the body). . Related Research News FDA Approves Repotrectinib...
Read More
|
May 31, 2021
|
Treatment

Dabrafenib (Tafinlar)

Combination Therapy, Targeted TherapyApproved for: NSCLCBiomarker: BRAF Dabrafenib (Tafinlar) is a FDA-approved Targeted Therapy/Combination Therapy for non-small cell lung cancer that has metastasized (NSCLC) with the biomarker BRAF. It is used with trametinib. Dabrafenib is used only in patients...
Read More
|
May 31, 2021
|
Treatment

Osimertinib (Tagrisso)

Targeted TherapyApproved for: NSCLCEGFR Osimertinib (Tagrisso) is a FDA-approved targeted therapy for non-small cell lung cancer (NSCLC) in adults whose tumors have certain EGFR gene mutations. It is used: As adjuvant therapy after surgery to remove the tumor, As...
Read More
|
May 30, 2021
|
Treatment

Dacomitinib (Vizimpro)

Targeted TherapyApproved for: NSCLCBiomarker: EGFR Dacomitinib (Vizimpro) is a FDA-approved treatment for Non-small cell lung cancer (NSCLC) that has metastasized (spread to other parts of the body). It is used as first-line treatment in patients whose tumors have certain...
Read More
|
May 27, 2021
|
Treatment
1 2